| Univariate | Multivariate | ||
---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age (per 10 years) | 1.503 (1.358–1.671) | < 0.001 | 1.293 (1.147–1.463) | < 0.001 |
Gender | ||||
 Female | 1.00 | - |  |  |
 Male | 1.010 (0.724–1.411) | 0.954 |  |  |
Body mass index (per point) | 0.986 (0.940–1.034) | 0.564 |  |  |
Vaccination | ||||
 Reference* | 1.00 | - | 1.00 | - |
 Fully vaccinated | 0.270 (0.170–0.420) | < 0.001 | 0.629 (0.416–0.952) | 0.028 |
 Boosted | 0.278 (0.182–0.420) | < 0.001 | ||
Symptomatic | ||||
 No | 1.00 | - |  |  |
 Yes | 0.827 (0.590–1.161) | 0.272 |  |  |
Disease severity | ||||
 Reference†| 1.00 | - | 1.00 | - |
 Moderate | 2.143 (1.475–3.116) | < 0.001 | 1.155 (0.749–1.772) | 0.511 |
Charlson comorbidity index (per point) | 1.581 (1.390–1.811) | < 0.001 | 1.247 (1.075–1.455) | 0.004 |
Antiviral treatment | ||||
 No | 1.00 | - |  |  |
 Yes | 0.570 (0.331–0.949) | 0.036 | 0.558 (0.314–0.961) | 0.040 |